1. asymptomatic covid-19 patients ； 2. hypercalcemia; 3. history of primary hyperparathyroidism; 4. history of triple hyperparathyroidism; 5. patients who are allergic to calcitriol; 6. pregnant or lactating women; 7. patients with severe heart or lung diseases or tumor history; 8. patients already taking vitamin d or its similar preparations; 9. participants in other interventional clinical studies (including taking paxlovid); 10. patients with renal insufficiency (egfr\<60ml/min/1.73m2); 11. patients considered unsuitable for this study by the investigator；

1. asymptomatic covid-19 patients ； 2. hypercalcemia; 3. history of primary hyperparathyroidism; 4. history of triple hyperparathyroidism; 5. patients who are allergic to calcitriol; 6. pregnant or lactating women; 7. patients with severe heart or lung diseases or tumor history; 8. patients already taking vitamin d or its similar preparations; 9. participants in other interventional clinical studies (including taking paxlovid); 10. patients with renal insufficiency (egfr\<60ml/min/1.73m2); 11. patients considered unsuitable for this study by the investigator；

asymptomatic covid-19 patients ； hypercalcemia; history of primary hyperparathyroidism; history of triple hyperparathyroidism; patients who are allergic to calcitriol; pregnant or lactating women; patients with severe heart or lung diseases or tumor history; patients already taking vitamin d or its similar preparations; participants in other interventional clinical studies (including taking paxlovid); patients with renal insufficiency (egfr<60ml/min/1.73m2); patients considered unsuitable for this study by the investigator；

asymptomatic covid-19 patients ； hypercalcemia; history of primary hyperparathyroidism; history of triple hyperparathyroidism; patients who are allergic to calcitriol; pregnant or lactating women; patients with severe heart or lung diseases or tumor history; patients already taking vitamin d or its similar preparations; participants in other interventional clinical studies (including taking paxlovid); patients with renal insufficiency (egfr<60ml/min/1.73m2); patients considered unsuitable for this study by the investigator；